Atheroprotective mechanisms of HDL

Atherosclerosis

Volumn 144, Issue 2, 1999, Pages 285-301

  Stein, Olga ^a   Stein, Yechezkiel ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Apolipoproteins; Atherosclerosis; CETP; Cholesterol efflux; LCAT; Phospholipids; RCT in vivo; SR B1

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; CAVEOLIN; CELL ADHESION MOLECULE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CHOLESTEROL TRANSPORT; HEART INFARCTION PREVENTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TANGIER DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; APOLIPOPROTEINS; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ARTERIOSCLEROSIS; GLYCOPROTEINS; HUMANS; LIPOPROTEINS, HDL; MICE; MICE, TRANSGENIC; PHOSPHOLIPIDS; RABBITS; RISK FACTORS;

EID: 0033017132     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00065-9     Document Type: Review

References (208)

1. Stein O., Stein Y. The removal of cholesterol from Landschutz ascites cells by high density apolipoprotein. Biochim Biophys Acta. 326:1973;232-244.
2. Bates S.R., Rothblat G.H. Regulation of cellular sterol flux and synthesis by human serum lipoproteins. Biochim Biophys Acta. 360:1974;38-55.
3. Jackson R.L., Stein O., Gotto A.M., Stein Y. A comparative study on the removal of cellular lipids from Landschutz ascites cells by human plasma apolipoproteins. J Biol Chem. 250:1975;7204-7209.
4. 1 in the cholesterol-removing capacity of lipoprotein-deficient serum in tissue culture. Biochim Biophys Acta. 574:1979;495-504.
5. Sloop C.H., Dory L., Roheim P.S. Interstitial fluid lipoproteins. J Lipid Res. 28:1987;225-237.
6. Castro G.R., Fielding C.J. Early incorporation of cell derived cholesterol into pre-β-migrating HDL. Biochemistry. 27:1988;25-29.
7. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res. 36:1995;211-218.
8. Asztalos B.F., Sloop C.H., Wong L., Roheim P.S. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apoA-I containing subpopulations. Biochim Biophys Acta. 1169:1993;291-300.
9. Forte T.M., Bielicki J.K., Goth-Goldstein R., Selmek J., McCall M.R. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J Lipid Res. 36:1995;148-157.
10. Asztalos B.F., Zhang W., Roheim P.S., Wong L. Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre α migrating high density lipoprotein particles. Arterioscler Thromb Vasc Biol. 17:1997;1630-1636.
11. Asztalos B.F., Sloop C.H., Wong L., Roheim P.S. Comparison of apoA-I-containing subpopulations of dog plasma and prenodal peripheral lymph: evidence for alteration in subpopulations in the interstitial space. Biochim Biophys Acta. 1169:1993;301-304.
12. Wong L., Sivok B., Kurucz E., Sloop C.H., Roheim P.S., Asztalos B. Lipid composition of HDL subfractions in dog plasma and lymph. Arterioscler Thromb Vasc Biol. 15:1995;1875-1881.
13. 1-HDL. Biochim Biophys Acta. 1301:1996;255-262.
14. Hara H., Yokoyama S. Interaction of free apolipoproteins with macrophages - formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem. 266:1991;3080-3086.
15. Bielicki J.K., Johnson W.J., Weinberg R.B., Glick J.M., Rothblat G.H. Efflux of lipid from fibroblasts to apolipoproteins: dependence on elevated levels of cellular unesterified cholesterol. J Lipid Res. 33:1992;1699-1709.
16. Forte T.M., Goth-Goldstein R., Nordhausen R.W., McCall M.R. Apolipoprotein A-I-cell membrane interaction: extracellular assembly of heterogeneous nascent HDL particles. J Lipid Res. 34:1993;317-324.
17. Zhang W., Asztalos B., Roheim P.S., Wong L. Characterization of phospholipids in pre-α HDL: selective phospholipid efflux with apolipoprotein A-I. J Lipid Res. 39:1998;1-7.
18. Huang Y., von Eckardstein A., Wu S., Maeda N., Assmann G. A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA. 91:1994;1834-1838.
19. von Eckardstein A., Huang Y., Wu S., Funke H., Noseda G., Assmann G. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Arterioscler Thromb Vasc Biol. 15:1995;691-703.
20. Huang Y., von Eckardstein A., Wu S., Assmann G. Effects of the apolipoprotein E-polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest. 96:1995;2693-2701.
21. Burns C.H., Rothblat G.H. Cholesterol excretion by tissue culture cells: Effect of serum lipids. Biochim Biophys Acta. 176:1969;616-625.
22. Stein Y., Glangeaud M.C., Fainaru M., Stein O. The removal of cholesterol from aortic smooth muscle cells in culture and Landschutz ascites cells by fractions of human high density apolipoprotein. Biochim Biophys Acta. 380:1975;106-118.
23. Stein O., Stein Y., Lefevre M., Roheim P.S. The role of apoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. Biochim Biophys Acta. 878:1986;7-13.
24. Hara S., Shike T., Takasu N., Mizui T. Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells. Arterioscler Thromb Vasc Biol. 17:1997;1258-1266.
25. Fournier N., de la Llera-Moya M., Burkey B.F., Swaney J.B., Paterniti J. Jr, Moatti N., Atger V., Rothblat G.H. Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res. 37:1996;1704-1711.
26. Fournier N., Paul J.L., Atger A., Cogny A., Soni T., de la Llera-Moya M., Rothblat G., Moatti N. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol. 17:1997;2685-2691.
27. Stein O., Dabach Y., Hollander G., Ben-Naim M., Halperin G., Breslow J.L., Stein Y. Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice. Proc Natl Acad Sci USA. 94:1997;9820-9824.
28. Kunz F., Pechlaner C., Erhart R., Fend F., Mühlberger V. HDL and plasma phospholipids in coronary artery disease. Arterioscler Thromb. 14:1994;1146-1150.
29. Groener J.E.M., Scheek L.M., van Ramshorst E., Krauss X.H., van Tol A. Delayed increase in high density lipoprotein-phospholipids after ingestion of a fat load in normolipidemic patients with coronary artery disease. Atherosclerosis. 137:1998;311-319.
30. Barbaras R., Grimaldi P., Negrel R., Ailhaud G. Characterization of high-density lipoprotein binding and cholesterol efflux in cultured mouse adipose cells. Biochim Biophys Acta. 888:1986;143-156.
31. Steinmetz A., Barbaras R., Ghalim N., Clavey V., Fruchart J.C., Ailhaud G. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem. 265:1990;7859-7863.
32. Barbaras R., Puchois P., Fruchart J.C., Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI;AII particles. Biochem Biophys Res Commun. 142:1987;63-69.
33. Mahlberg F.H., Rothblat G.H. Cellular cholesterol efflux. Role of cell membrane kinetic pools and interaction with apolipoproteins AI, AII, and Cs. J Biol Chem. 267:1992;4541-4550.
34. Oikawa S., Mendez A.J., Oram J.F., Bierman E.L., Cheung M.C. Effects of high-density lipoprotein particles containing apo A-I, with or without apo A-II, on intracellular cholesterol efflux. Biochim Biophys Acta. 1165:1993;327-334.
35. 3H]cholesterol efflux and uptake in cell culture. Biochim Biophys Acta. 1257:1995;174-180.
36. Skarlatos S.I., Duverger N., Rader D., Kruth H.S. Cholesterol efflux from human monocyte-derived macrophages in the presence of LpA-I:A-II. Biochim Biophys Acta. 1270:1995;19-25.
37. Castro G., Nihoul L.P., Dengremont C., de Geitere C., Delfly B., Tailleux A., Fievet C., Duverger N., Denefle P., Fruchart J.C., Rubin E.M. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 36:1997;2243-2249.
38. Castellani L.W., Navab M., van Lenten B.J., Hedrick C.C., Hama S.Y., Goto A.M., Fogelman A.M., Lusis A.J. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest. 100:1997;464-474.
39. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265-267.
40. Duverger N., Kruth H., Emmanuel F., Caillaud J.M., Viglietta C., Castro G., Tailleux A., Fievet C., Fruchart J.C., Houdebine L.M., Denefle P. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 94:1996;713-717.
41. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA. 91:1994;9607-9611.
42. Paszty C., Maeda N., Verstuyft J., Rubin E.M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 94:1994;899-903.
43. Schultz J.R., Gong E.L., McCall M.R., Nichols A.V., Clift S.M., Rubin E.M. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J Biol Chem. 267:1992;21630-21636.
44. Schultz J.R., Verstuyft J.G., Gong E.L., Nichols A.V., Rubin E.M. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 365:1993;762-764.
45. Holvoet P., Danloy S., Deridder E., Lox M., Bernar H., Dhoest A., Collen D. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice. J Clin Invest. 102:1998;379-385.
46. Warden C.H., Hedrick C.C., Qiao J.H., Castellani L.W., Lusis A.J. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 261:1993;469-472.
47. Weinberg R.B., Spector M.S. Structural properties and lipid binding of human apolipoprotein A-IV. J Biol Chem. 260:1985;4914-4921.
48. Roheim P.S., Edelstein D., Pinter G.G. Apolipoproteins in rat serum and renal lymph. Proc Natl Acad Sci USA. 73:1976;1757-1760.
49. Sloop C.H., Dory L., Hamilton R., Krause B.R., Roheim P.S. Characterization of dog peripheral lymph lipoproteins: the presence of a disc-shaped 'nascent' high density lipoprotein. J Lipid Res. 24:1983;1429-1440.
50. Duverger N., Tremp G., Caillaud J.M., Emmanuel F., Castro G., Fruchart J.C., Steinmetz A., Denefle P. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 273:1996;966-968.
51. Cohen R.D., Castellani L.W., Qiao J.H., van Lenten B.J., Lusis A.J., Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest. 99:1997;1906-1916.
52. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J.G., Rubin E.M., Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1992;343-353.
53. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:1992;468-471.
54. Basu S.K., Ho Y.K. Brown MS, Bilheimer DW, Anderson RG, Goldstein JL. Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes. J Biol Chem. 257:1982;9788-9795.
55. Mazzone T. Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol. 7:1996;303-307.
56. Bellosta S., Mahley R.W., Sanan D.A., Murata J., Newland D.L., Taylor J.M., Pitas R.E. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 96:1995;2170-2179.
57. Zhu Y., Bellosta S., Langer C., Bernini F., Pitas R.E., Mahley R.W., Assmann G., von Eckardstein A. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc Natl Acad Sci USA. 95:1998;7585-7590.
58. Fazio S., Babaev V.R., Murray A.B., Hasty A.H., Carter K.G., Gleaves L.A., Atkinson J.B., Linton M.F. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA. 94:1997;4647-4652.
59. 3 binding to macrophages. J Lipid Res. 39:1998;293-301.
60. Zhang W.Y., Gaynor P.M., Kruth H.S. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem. 271:1996;28641-28646.
61. Huang Y.D., Zhu Y.H., Langer C., Raabe M., Wu S.L., Wiesenhutter B., Seedorf U., Maeda N., Assmann G., von Eckardstein A. Effects of genotype and diet on cholesterol efflux into plasma and lipoproteins of normal apolipoprotein AI and apolipoprotein E deficient mice. Arter Thromb Vasc Biol. 17:1997;2010-2019.
62. Cullen P., Cignarella A., Brennhausen B., Mohr S., Assmann G., von Eckardstein A. Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest. 101:1998;1670-1677.
63. Zhang S.H., Reddick R.L., Avdievich E., Surles L.K., Jones R.G., Reynolds J.B., Quarfordt S.H., Maeda N. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest. 99:1997;2858-2866.
64. Bird D.A., Tangirala R.K., Fruebis J., Steinberg D., Witztum J.L., Palinski W. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J Lipid Res. 39:1998;1079-1090.
65. Hockland B.M., Slotte J.P., Bierman E.L., Oram J.F. Cyclic AMP stimulates efflux of intracellular sterol from cholesterol-loaded cells. J Biol Chem. 268:1993;25343-25349.
66. Li Q., Tsujita M., Yokoyama S. Selective down-regulation by protein kinase C inhibitors of apolipoprotein-mediated cellular cholesterol efflux in macrophages. Biochemistry. 36:1997;12045-12052.
67. Smith J.D., Miyata M., Ginsberg M., Grigaux C., Shmookler E., Plump A.S. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem. 271:1996;30647-30655.
68. Middleton A., Middleton B. Elevation of cyclic AMP by iloprost and prostaglandin E-1 increases cholesterol efflux and the binding capacity for high-density lipoproteins in human fibroblasts. Biochim Biophys Acta. 1391:1998;117-132.
69. Rothberg K.G., Ying Y.S., Kamen B.A., Anderson R.G. Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J Cell Biol. 111:1990;2931-2938.
70. Rothberg K.G., Heuser J.E., Donzell W.C., Ying Y.S., Glenney J.R., Anderson R.G. Caveolin, a protein component of caveolae membrane coats. Cell. 68:1992;673-682.
71. Smart E.J., Ying Y.S., Conrad P.A., Anderson R.G. Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J Cell Biol. 127:1994;1185-1197.
72. Moon B.Y., Higashi S., Gombos Z., Murata N. Unsaturation of the membrane lipids of chloroplasts stabilizes the photosynthetic machinery against low-temperature photo-inhibition in transgenic tobacco plants. Proc Natl Acad Sci USA. 92:1995;6219-6223.
73. Murata M., Peranen J., Schreiner R., Wieland F., Kurzchalia T.V., Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA. 92:1995;10339-10343.
74. Conrad P.A., Smart E.J., Ying Y.S., Anderson R.G., Bloom G.S. Caveolin cycles between plasma membrane caveolae and the Golgi complex by microtubule-dependent and microtubule-independent steps. J Cell Biol. 131:1995;1421-1433.
75. Smart E.J., Ying Y.s, Donzell W.C., Anderson R.G. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol Chem. 271:1996;29427-29435.
76. Uittenbogaard A., Ying Y., Smart E.J. Characterization of a cytosolic heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. J Biol Chem. 273:1998;6525-6532.
77. Fielding P.E., Fielding C.J. Plasma membrane caveolae mediate the efflux of cellular free cholesterol. Biochemistry. 34:1995;14288-14292.
78. Fielding P.E., Fielding C.J. Intracellular transport of low density lipoprotein derived free cholesterol begins at clathrin-coated pits and terminates at cell surface caveolae. Biochemistry. 35:1996;14932-14938.
79. Gillotte K.L., Davidson W.S., Lund-Katz S., Rothblat G.H., Phillips M.C. Removal of cellular cholesterol by pre-β-HDL involves plasma membrane microsolubilization. J Lipid Res. 39:1998;1918-1928.
80. Fielding C.J., Bist A., Fielding P.E. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci USA. 94:1997;3753-3758.
81. Bist A., Fielding P.E., Fielding C.J. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci USA. 94:1997;10693-10698.
82. Babitt J., Trigatti B., Rigotti A., Smart E.J., Anderson R.G., Xu S., Krieger M. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem. 272:1997;13242-13249.
83. Stein Y., Dabach Y., Hollander G., Halperin G., Stein O. Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether. Biochim Biophys Acta. 752:1983;98-105.
84. Glass C., Pittman R.C., Weinstein D.W., Steinberg D. Dissociation of tissue uptake of cholesterol from that of apoprotein A-I of rat high density lipoproteins: selective delivery of cholesterol to liver, adrenal and gonad. Proc Natl Acad Sci USA. 80:1983;5435-5439.
85. 125I by cultured rat hepatocytes and adrenal cells. Biochim Biophys Acta. 796:1984;72-82.
86. Glass C., Pittman R.C., Civen M., Steinberg D. Uptake of high density lipoprotein-associated apoprotein A-I and cholesteryl esters by 16 tissues of the rat in vivo and by adrenal glands and hepatocytes in vitro. J Biol Chem. 260:1985;744-750.
87. Leitersdorf E., Israeli A., Stein O., Eisenberg S., Stein Y. The role of apolipoproteins of HDL in the selective uptake of cholesteryl linoleyl ether by cultured rat and bovine adrenal cells. Biochim Biophys Acta. 878:1986;320-329.
88. Stein O., Israeli A., Leitersdorf E., Halperin G., Stein Y. Preferential uptake of cholesteryl ester-HDL by cultured macrophages. Atherosclerosis. 65:1987;151-158.
89. 3 by bovine adrenal membranes. Biochim Biophys Acta. 902:1987;128-132.
90. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271:1996;518-520.
91. Rigotti A., Edelman E.R., Seifert P., Iqbal S., DeMattos R.B., Temel R.E., Krieger M., Williams D.L. Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. J Biol Chem. 271:1996;33545-33549.
92. Landschulz K.T., Pathak R.K., Rigotti A., Krieger M., Hobbs H.H. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest. 98:1996;984-995.
93. Plump A.S., Erickson S.K., Weng W., Partin J.S., Breslow J.L., Williams D.L. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J Clin Invest. 97:1996;2660-2671.
94. Wang N., Weng W., Breslow J.L., Tall A.R. Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. J Biol Chem. 271:1996;21001-21004.
95. Fluiter K., van der Westhuijzen D.R., van Berkel T.J.C. In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells. J Biol Chem. 273:1998;8434-8438.
96. Ng D.S., Francone O.L., Forte T.M., Zhang J., Haghpassand M., Rubin E.M. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J Biol Chem. 272:1997;15777-15781.
97. Komaromy M., Azhar S., Cooper A.D. Chinese hamster ovary cells expressing a cell surface-anchored form of hepatic lipase. Characterization of low density lipoprotein and chylomicron remnant uptake and selective uptake of high density lipoprotein-cholesteryl ester. J Biol Chem. 271:1996;16906-16914.
98. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S.H., Edelman E.R., Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 387:1997;414-417.
99. Wang N., Arai T., Ji Y., Rinninger F., Tall A.R. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem. 273:1998;32920-32926.
100. Rigotti A., Trigatti B.L., Penman M., Rayburn H., Herz J., Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA. 94:1997;12610-12615.
101. Varban M.L., Rinninger F., Wang N., Fairchild-Huntress V., Dunmore J.H., Fang Q., Gosselin M.L., Dixon K.L., Deeds J.D., Acton S.L., Tall A.R., Huszar D. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci USA. 95:1998;4619-4624.
102. Ji Y., Jian B., Wang N., Sun Y., de la Llera Moya M., Phillips M.C., Rothblat G.H., Swaney J.B., Tall A.R. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem. 272:1997;20982-20985.
103. Stein O., Dabach Y., Hollander G., Ben-Naim M., Halperin G., Okon E., Stein Y. Cholesterol efflux in vivo from a depot of cationized LDL injected into a thigh muscle of small rodents. Atherosclerosis. 133:1997;15-22.
104. Voyiaziakis E., Golberg I.J., Plump A.S., Rubin E.M., Breslow J.L., Huang L.S. Apo A-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apo B transgenic mice. J Lipid Res. 39:1998;313-321.
105. Stein O., Dabach Y., Hollander G., Ben-Naim M., Halperin G., Stein Y. Dexamethasone impairs cholesterol egress from a localized lipoprotein depot in vivo. Atherosclerosis. 137:1998;303-310.
106. Stein O, Dabach Y, Hollander G, Ben-Naim-M, Halperin G, Stein Y. High levels of human apolipoprotein A-I and HDL in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Relevance to regression of atherosclerosis? Atherosclerosis 1999. in press.
107. Berard A.M., Föger B., Remaley A., Shamburek R., Vaisman B.L., Talley G., Paigen B., Hoyt R.F. Jr, Marcovina S., Brewer H.B. Jr, Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 3:1997;744-749.
108. Pattnaik N.M., Montes A., Hughes L.B., Zilversmit D.B. Cholesteryl ester exchange protein in human plasma isolation and characterization. Biochim Biophys Acta. 530:1978;428-438.
109. Son Y.S., Zilversmit D.B. Increased lipid transfer activities in hyperlipidemic rabbit plasma. Arteriosclerosis. 6:1986;345-351.
110. Stein Y., Dabach Y., Hollander G., Stein O. Cholesteryl ester transfer activity in hamster plasma: increase by fat and cholesterol rich diets. Biochim Biophys Acta. 1042:1990;138-141.
111. Marotti K.R., Castle C.K., Boyle Y.P., Lin A.H., Murray R.W., Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature (London). 364:1993;73-75.
112. Hayek T., Chajek-Shaul T., Walsh A., Agellon L.B., Moulin P., Tall A.R., Breslow J.L. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J Clin Invest. 90:1992;505-510.
113. Hayek T., Masucci-Magoulas L., Jiang X., Walsh A., Rubin E., Breslow J.L., Tall A.R. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 96:1995;2071-2074.
114. Hayek T., Azrolan N., Verdery R.B., Walsh A., Chajek-Shaul T., Agellon L.B., Tall A.R., Breslow J.L. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism Studies in transgenic mice. J Clin Invest. 92:1993;1143-1152.
115. Francone O.L., Royer L., Haghpassand M. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res. 37:1996;1268-1277.
116. Tato F., Vega G.L., Grundy S.M. Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations. Arterioscler Thromb Vasc Biol. 15:1995;446-451.
117. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., de Knijff P., McPherson R., Bruschke A.V.G., Lie K.I., Kastelein J.J.P. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl J Med. 338:1998;86-93.
118. Kakko S., Tamminen M., Kesaniemi Y.A., Savolainen M.J. R451Q mutation in the cholesteryl ester transfer protein (CETP) gene is associated with high plasma CETP activity. Atherosclerosis. 136:1998;233-240.
119. Breckenridge W.C., Little J.A., Alaupovic P., Wang C.S., Kuksis A., Kakis G., Lindgren F., Gardiner G. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 45:1982;161-179.
120. Hegele R.A., Little J.A., Vezina C., Maguire G.F., Tu L., Wolever T.S., Jenkins D.J., Connelly P.W. Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb. 13:1993;720-728.
121. Homanics G.E., de Silva H.V., Osada J., Zhang S.H., Wong H., Borensztajn J., Maeda N. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J Biol Chem. 270:1995;2974-2980.
122. Santamarina-Fojo S., Haudenschild C., Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 9:1998;211-219.
123. Fan J., Wang J., Bensadoun A., Lauer S.J., Dang Q., Mahley R.W., Taylor J.M. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci USA. 91:1994;8724-8728.
124. Busch S.J., Bamhart R.L., Martin G.A., Fitzgerald M.C., Yates M.T., Mao S.J., Thomas C.E., Jackson R.L. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem. 269:1994;16376-16382.
125. Dichek H.L., Brecht W., Fan J., Ji Z.S., McCormick S.P.A., Akeefe H., Conzo L.A., Sanan D.A., Weisgraber K.H., Young S.G., Taylor J.M., Mahley R.W. Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. J Biol Chem. 273:1998;1896-1903.
126. Ji Z.S., Dichek H.L., Miranda R.D., Mahley R.W. Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem. 272:1997;31285-31292.
127. Blades B., Vega G.L., Grundy S.M. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler Thromb. 13:1993;1227-1235.
128. Mezdour H., Jones R., Dengremont C., Castro G., Maeda N. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem. 272:1997;13570-13575.
129. Amar M.J., Vaisman B.I., Foger B., Paigen B., Talley G.D., Brewer H.B. Jr, Santamarina-Fojo S. The effect of hepatic lipase deficiency on the plasma lipids, lipoproteins and diet-induced atherosclerosis in LCAT transgenic mice. Circulation. 96:1997;1-109. Abstract.
130. Zhong S., Goldberg I.J., Bruce C., Rubin E., Breslow J.L., Tall A. Human apoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest. 94:1994;2457-2467.
131. Fredrickson D.S., Altrocchi P.H., Avioli L.V., Goodman D.S., Goodman H.C. Tangier disease-combined clinical staff conference at the National Institutes of Health. Ann Intern Med. 55:1961;1016-1021.
132. Bojanovski D., Gregg R.E., Zech L.A., Meng M.S., Bishop C., Ronan R., Brewer H.B. Jr In vivo metabolism of proapolipoprotein A-I in Tangier disease. J Clin Invest. 80:1987;1742-1747.
133. Assmann G.A., von Eckardstein A., Brewer H.B. Familial HDL deficiency: Tangier disease. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic Basis of Inherited Disease. 1995;2053-2072 McGraw-Hill, New York.
134. Francis G.A., Knopp R.H., Oram J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest. 96:1995;78-87.
135. Remaley A.T., Schumacher U.K., Stonik J.A., Farsi B.D., Nazih H., Brewer H.B. Jr Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler Thromb Vasc Biol. 17:1997;1813-1821.
136. von Eckardstein A., Chirazi A., Schuler-Lüttmann S., Walter M., Kastelein J.J., Giesel J., Real J.T., Miccoli R., Noseda G., Höbbel G., Assmann G. Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I. J Lipid Res. 39:1998;987-998.
137. Eberhart G.P., Mendez A.J., Freeman M.W. Decreased cholesterol efflux from fibroblasts of a patient without Tangier disease, but with markedly reduced high density lipoprotein cholesterol levels. J Clin Endocrinol Metab. 83:1998;836-846.
138. Rust S., Walter M., Funke H., von Eckardstein A., Cullen P., Kroes H.Y., Hordijk R., Geisel J., Kastelein J., Molhuizen H.O., Schreiner M., Mischke A., Hahmann H.W., Assmann G. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat Genet. 20:1998;96-98.
139. Schaefer E.J., Heaton W.H., Wetzel M.G., Brewer H.B. Jr Plasma apolipoprotein A-I absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis. 2:1982;16-26.
140. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R. Jr, Bagdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 79:1989;8-15.
141. Schaefer E.J., Genest J.J. Jr, Ordovas J.M., Salem D.N., Wilson P.W.F. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis. 108:1994;S41-S54.
142. Cullen P., Funke H., Schulte H., Assmann G. Lipoproteins and cardiovascular risk-from genetics to CHD prevention. J Atheroscler Thromb. 4:1997;51-58.
143. Funke H. Genetic determinants of high density lipoproteins. Curr Opin Lipid. 8:1997;189-196.
144. Kuivenhoven J.A., Pritchard H., Hill J., Frohlich J., Assmann G., Kastelein J. The molecular pathway of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 38:1997;191-205.
145. Brown M.L., Inazu A., Hesler C.B., Agellon L.B., Mann C., Whitlock M.E., Marcel Y.L., Milne R.W., Koizumi J., Mabuchi H., Takeda R., Tall A.R. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature (London). 342:1989;448-451.
146. Takahashi K., Jiang X.C., Sakai N., Yamashita S., Hirano K., Bujo H., Yamazaki H., Kusunoki J., Miura T., Kussie P., Matsuzawa Y., Saito Y., Tall A.R. A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. J Clin Invest. 92:1993;2060-2064.
147. Inazu A., Jiang X.C., Haraki T., Kamon N., Koizumi J., Mabuchi H., Takeda R., Takata K., Moriyama Y., Doi M., Tall A.R. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest. 94:1994;1872-1882.
148. Chiba H., Akita H., Tsuchihashi K., Hui S.P., Takahashi Y., Fuda H., Suzuki H., Shibuya H., Tsuji M., Kobayashi K. Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. J Lipid Res. 38:1997;1204-1216.
149. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J., Tall A.R. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 97:1996;2917-2923.
150. Bruce C., Sharp D.S., Tall A.R. Relationship of HDL and CAD to a common amino acid polymorphism in the CETP in men with and without hypertriglyceridemia. J Lipid Res. 39:1998;1071-1078.
151. Haraki T., Inazu A., Yagi K., Kajinami K., Koizumi J., Mabuchi H. Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis. 132:1997;229-236.
152. Hirano K., Yamashita S., Nakajima N., Arai T., Maruyama T., Yoshida Y., Ishigami M., Sagai N., Kameda-Takemura K., Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 17:1997;1053-1059.
153. Glomset J.A. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 9:1968;155-167.
154. Hoeg J.M., Vaisman B.L., Demosky S.J. Jr, Meyn S.M., Talley G.D., Hoyt R.F. Jr, Feldman S., Berard A.M., Sakai N., Wood D., Brousseau M.E., Marcovina S., Brewer H.B. Jr, Santamarina-Fojo S. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem. 271:1996;4396-4402.
155. Brousseau M.E., Santamarina-Fojo S., Zech L.A., Berard A.M., Vaisman B.L., Meyn S.M., Powell D., Brewer H.B. Jr, Hoeg J.M. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. J Clin Invest. 97:1996;1844-1851.
156. Hoeg J.M., Santamarina-Fojo S., Berard A.M., Cornhill J.F., Herderick E.E., Feldman S.H., Haudenschild C.C., Vaisman B.L., Hoyt R.F. Jr, Demosky S.J. Jr, Kauffman R.D., Hazel C.M., Marcovina S.M., Brewer H.B. Jr Overexpression of lecithin: cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA. 93:1996;11448-11453.
157. Föger B., Vaisman B.L., Paigen B., Hoyt R.F. Jr, Brewer B. Jr, Santamarina-Fojo S. CETP modulates the development of aortic atherosclerosis in LCAT-transgenic mice. Circulation. November(Suppl 1):1997;110.
158. Brousseau M.E., Santamarina-Fojo S., Vaisman B.L., Applebaum-Bowden D., Berard A.M., Talley G.D., Brewer H.B. Jr, Hoeg J.M. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. J Lipid Res. 38:1997;2537-2547.
159. Castelli W.P., Doyle J.T., Gordon T., Hames C.G., Hjortland M.C., Hulley S.B., Kagan A., Zukel W.J. Alcohol and blood lipids. The cooperative lipoprotein phenotyping study. Lancet. 2:1977;153-155.
160. Moore R.D., Pearson T.A. Moderate alcohol consumption and coronary artery disease. A review. Medicine. 65:1986;242-267.
161. Hegsted D.M., Ausman L.M. Diet, alcohol and coronary heart disease in men. J Nutr. 118:1988;1184-1189.
162. Taskinen M.R., Valimaki M., Nikkila E.A., Kuusi T., Ehnholm C., Ylikahri R. High density lipoprotein subfractions and postheparin plasma lipases in alcoholic men before and after ethanol withdrawal. Metabolism. 31:1982;1168-1174.
163. Savolainen M.J., Hannuksela M., Seppanen S., Kervinen K., Kesaniemi Y.A. Increased high-density lipoprotein cholesterol concentration in alcoholics is related to low cholesteryl ester transfer protein activity. Eur J Clin Invest. 20:1990;593-599.
164. Emeson E.E., Manaves V., Singer T., Tabesh M. Chronic alcohol feeding inhibits atherogenesis in C57BL/6 hyperlipidemic mice. Am J Pathol. 147:1995;1749-1758.
165. Dai J., Miller B.A., Lin R.C. Alcohol feeding impedes early atherosclerosis in low-density lipoprotein receptor knockout mice: factors in addition to high-density lipoprotein-apolipoprotein AI are involved. Alcohol Clin Exp Res. 21:1997;11-18.
166. Nagano Y., Arai H., Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA. 88:1991;6457-6461.
167. Salmon S., Maziere C., Auclair M., Theron L., Santus R., Maziere J.C. Malondialdehyde modification and copper-induced autooxidation of high-density lipoprotein decrease cholesterol efflux from human cultured fibroblasts. Biochim Biophys Acta. 1125:1992;230-235.
168. Morel D.W. Reduced cholesterol efflux to mildly oxidized high density lipoprotein. Biochem Biophys Res Commun. 200:1994;408-416.
169. Rifici V.A., Khachadurian A.K. Oxidation of high density lipoproteins: characterization and effects on cholesterol efflux from J774 macrophages. Biochim Biophys Acta. 1299:1996;87-94.
170. Gesquiere L., Loreau N., Blache D. Impaired cellular cholesterol efflux by oxysterol-enriched high density lipoproteins. Free Radic Biol Med. 23:1997;541-547.
171. Ueyama K., Yokode M., Arai H., Nagano Y., Li Z.X., Cho M., Kita T. Cholesterol efflux effect of high density lipoprotein is impaired by whole cigarette smoke extracts through lipid peroxidation. Free Radic Biol Med. 24:1998;182-190.
172. Wang W.Q., Merriam D.L., Moses A.S., Francis G.A. Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers. J Biol Chem. 273:1998;17391-17398.
173. Ishigami M., Yamashita S., Sakai N., Hirano K.-I., Arai T., Maruyama T., Takami S., Koyama M., Kameda-Takemura K., Matsuzawa Y. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 27:1997;285-292.
174. Tsujita M., Yokoyama S. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol. Biochemistry. 35:1996;13011-13020.
175. Mackness M.I., Arrol S., Abbott C., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129-135.
176. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 96:1995;2882-2891.
177. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J., Shih D.M., Van Lenten B.J., Frank J.S., Demer L.L., Edwards P.A., Fogelman A.M. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Dis. 16:1996;831-842.
178. Shih D.M., Gu L., Hama S., Xia Y.R., Navab M., Fogelman A.M., Lusis A.J. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 97:1996;1630-1639.
179. Navab M., Hama-Levy S., van Lenten B.J., Fonarow G.C., Cardinez C.J., Castellani L.W., Brennan M.L., Lusis A.J., Fogelman A.M. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 99:1997;2005-2019.
180. Blatter M.C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 211:1993;871-879.
181. Shih D.M., Gu L., Xia Y.-R., Navab M., Li W.-F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.
182. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 101:1998;1581-1590.
183. Ruiz J., Blanche H., James R.W., Garin M.C., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Gin-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
184. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 96:1995;3005-3008.
185. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 52:1993;598-608.
186. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 3:1993;73-76.
187. Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism met-leu54 is associated with modified serum concentrations of the enzyme. J Clin Invest. 99:1997;62-66.
188. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 17:1997;1067-1073.
189. Sanghera D.K., Aston C.E., Saha N., Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 62:1998;36-44.
190. Zama T., Murata M., Matsubara Y., Kawano K., Aoki N., Yoshino H., Watanabe G., Ishikawa K., Ikeda Y. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Dis. 17:1997;3565-3569.
191. Antikainen M., Murtomaki S., Syvanne M., Pahlman R., Tahvanainen E., Jauhiainen M., Frick M.H., Ehnholm C. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. 98:1996;883-885.
192. Herrmann S.M., Blanc H., Poirier O., Arveiler D., Luc G., Evans A., Marques-Vidal P., Bard J.M., Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 126:1996;299-303.
193. Sanghera D.K., Saha N., Kamboh M.I. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 136:1998;217-223.
194. Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C., Harmony J.A. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:1994;832-839.
195. Gelissen I.C., Hochgrebe T., Wilson M.R., Easterbrook Smith S.B., Jessup W., Dean R.T., Brown A.J. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem J. 331:1998;231-237.
196. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:1990;160-162.
197. Yokoyama M., Hirata K., Miyake R., Akita H., Ishikawa Y., Fukuzaki H. Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. Biochem Biophys Res Commun. 168:1990;301-308.
198. Kugiyama K., Sakamoto T., Misumi I., Sugiyama S., Ohgushi M., Ogawa H., Horiguchi M., Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res. 73:1993;335-343.
199. Murohara T., Kugiyama K., Ohgushi M., Sugiyama S., Ohta Y., Yasue H. LPC in oxidized LDL elicits vasocontraction and inhibits endothelium-dependent relaxation. Am J Physiol. 267:1994;H2441-H2449.
200. Matsuda Y., Hirata K., Inoue N., Suematsu M., Kawashima S., Akita H., Yokoyama M. High-density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res. 72:1993;1103-1109.
201. Plane F., Bruckdorfer K.R., Kerr P., Steuer A., Jacobs M. Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium-derived nitric oxide in rabbit aorta. Br J Pharmacol. 105:1992;216-222.
202. Deckert V., Persegol L., Viens L., Lizard G., Athias A., Lallemant C., Gambert P., Lagrost L. Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation. 95:1997;723-731.
203. Galle J., Ochslen M., Schollmeyer P., Wanner C. Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein. Hypertension. 23:1994;556-564.
204. Ota Y., Kugiyama K., Sugiyama S., Matsumura T., Terano T., Yasue H. Complexes of apoA-I with phosphatidylcholine suppress dysregulation of arterial tone by oxidized LDL. Am J Physiol. 273:1997;1215-1222.
205. Lebuffe G., Boullier A., Tailleux A., Delfly B., Dupuis B., Fruchart J.C., Duverger N., Emmanuel F., Denefle P., Vallet B., Duriez P. Endothelial derived vasorelaxation is impaired in human Apo A-I transgenic rabbits. Biochem Biophys Res Comm. 241:1997;205-211.
206. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 15:1995;1987-1994.
207. Ashby D.T., Rye K.A., Clay M.A., Vadas M.A., Gamble J.R., Barter P.J. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 18:1998;1450-1455.
208. Calabresi L., Franceschini G., Sirtori C.R., de Palma A., Sarasella M., Ferrante P., Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun. 238:1997;61-65.